These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 12386269

  • 1. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
    Takahashi F, Furuichi T, Yorozu K, Kawata S, Kitamura H, Kubodera N, Slatopolsky E.
    Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
    [Abstract] [Full Text] [Related]

  • 2. A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats.
    Hirata M, Endo K, Ohkawa H, Kumaki K, Kubodera N, Slatopolsky E, Kurokawa K, Fukagawa M.
    Nephrol Dial Transplant; 2002; 17 Suppl 10():37-40. PubMed ID: 12386267
    [Abstract] [Full Text] [Related]

  • 3. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
    Hirata M, Endo K, Katsumata K, Ichikawa F, Kubodera N, Fukagawa M.
    Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. [Effects of intravenous and oral OCT on secondary hyperparathyroidism in dogs with chronic renal failure].
    Takahashi F, Yorozu K, Kawata Y, Kitamura H, Chiba N, Kubodera N, Slatopolsky E.
    Clin Calcium; 2002 Jun; 12(6):741-8. PubMed ID: 15775360
    [Abstract] [Full Text] [Related]

  • 6. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH.
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [Abstract] [Full Text] [Related]

  • 7. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
    Kinugasa E, Akizawa T, Takahashi J, Nabeshima K, Ogata H, Nakayama F, Ideura T.
    Nephrol Dial Transplant; 2002 Mar; 17 Suppl 10():20-7. PubMed ID: 12386265
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F, Cubero JJ, Jimenez F, López JM, Aparicio A, Cid MC, Pizarro JL, Liso J, Santos I.
    Nephrol Dial Transplant; 1995 Mar; 10(5):665-70. PubMed ID: 7566580
    [Abstract] [Full Text] [Related]

  • 11. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study.
    Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, Slatopolsky E, Kurokawa K.
    Nephrol Dial Transplant; 2002 Mar; 17 Suppl 10():28-36. PubMed ID: 12386266
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S, Ueki K, Mashimo K, Tsukada Y, Naitoh M, Abe Y, Kawai H, Tsuchida A, Wakamatsu R, Nojima Y.
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [Abstract] [Full Text] [Related]

  • 14. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA.
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [Abstract] [Full Text] [Related]

  • 15. Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism.
    Hruby M, Ureña P, Mannstadt M, Schmitt F, Lacour B, Drüeke TB.
    Nephrol Dial Transplant; 1996 Sep; 11(9):1781-6. PubMed ID: 8918622
    [Abstract] [Full Text] [Related]

  • 16. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S, Akizawa T, Kurokawa K, Marumo F, Sakai O, Arakawa M, Morii H, Seino Y, Ogata E, Ohashi Y, Akiba T, Tsukamoto Y, Suzuki M.
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men.
    Brandi L, Egfjord M, Olgaard K.
    Nephrol Dial Transplant; 2002 May; 17(5):829-42. PubMed ID: 11981071
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA, DiBartola SP, Chew DJ, Nagode LA, Schenck PA, Rajala-Schultz PJ, Drost WT.
    J Vet Intern Med; 2006 May; 20(6):1307-13. PubMed ID: 17186842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.